Hypertensive Nephrosclerosis and Renovascular Disease — Viva Defence

Opening statement (SASPOP, delivered aloud)

"Mr Lawson is a 66-year-old man with established cardiovascular disease and genuinely resistant hypertension on two agents, complicated by a 25% creatinine rise since ramipril uptitration and an incidental 70% left renal artery ostial stenosis with preserved, symmetric kidney sizes. His main problems are: true resistance that needs its workup completed; a creatinine rise that is most consistent with the expected haemodynamic effect of ACE inhibition and is simultaneously a clue that the stenosis may be haemodynamically significant; diffuse atherosclerotic disease that drives his prognosis; and a decision — prompted by the surgical referral — about revascularisation, where the trial evidence supports optimal medical therapy. I would like to complete the resistant-hypertension evaluation, define the haemodynamic significance of the lesion, and agree a medical-first plan with him." [1] [3]

Structured problem list

1. Resistant hypertension — workup incomplete. Two agents is not three; the AHA definition requires failure of three agents including a diuretic at best-tolerated doses, confirmed out of office, with adherence verified [3].
2. Creatinine rise on ACE inhibition — 25%. Within the accepted haemodynamic range; a clue to renin-dependent physiology, not an indication to stop [4].
3. Incidental atherosclerotic left renal artery stenosis, 70%, kidneys preserved. Anatomy without a functional syndrome — the exact CORAL population [1].
4. Diffuse atherosclerotic disease — prior MI, ex-smoker; his dominant risk is coronary and cerebrovascular, not the renal artery [6].
5. The stent-or-not decision, on which he has been offered an intervention — needs an evidence-based shared decision [1].

Integrated management plan

• Complete the resistance workup: ambulatory or home readings to exclude white-coat effect; an honest adherence conversation; review for pressor drugs (NSAIDs, liquorice, sympathomimetics); screening bloods including electrolytes and an aldosterone-renin ratio — noting the ratio is harder to interpret on ramipril, which raises renin [3].
• Add the third agent properly — a calcium-channel blocker — since indapamide already provides the diuretic leg; target individualised intensive control given his risk profile, accepting that SPRINT supports lower targets in high-risk non-diabetic patients [7].
• Continue ramipril with monitoring. The 25% rise is acceptable; recheck creatinine and potassium at 1–2 weeks after any change. I would stop and investigate for bilateral or single-kidney disease only if the rise exceeded about 30% or function kept falling [4].
• Decline the stent, with reasons: CORAL randomised patients with stenosis over 60% plus hypertension or CKD to stent-plus-OMT versus OMT and found no difference in cardiovascular/renal events, mortality or blood pressure; ASTRAL found no renal-function benefit and documented periprocedural harm [1] [2].
• Treat the atheroma: high-intensity statin, antiplatelet therapy, complete smoking cessation, diabetic screening — the vascular-risk package that actually changes his prognosis [6].
• Set the triggers that would change my mind: recurrent flash pulmonary oedema, new contralateral disease making this effectively bilateral, or progressive GFR decline with a viable kidney — the subsets the trials did not enrol [5].

Probing questions with model answers

"The vascular surgeon says a 70% ostial lesion should be stented. Why are you refusing?" — "I'm not refusing; I'm selecting. CORAL enrolled exactly this anatomy — over 60% stenosis with hypertension or CKD — and stenting added nothing to medical therapy for events, mortality or pressure, with real periprocedural complications including dissection and atheroembolism. ASTRAL showed the same for renal function. The angiographic percentage is not the disease: by the time GFR falls in atherosclerotic RAS, the post-stenotic parenchyma has microvascular injury and fibrosis that a stent cannot reverse. What would move me is a functional syndrome — flash pulmonary oedema, bilateral tight disease, a single functioning kidney losing GFR." [1] [2] [4]

"His creatinine rose on ramipril. Doesn't that prove the drug is harming his kidney?" — "It proves the opposite physiology. Angiotensin II was constricting his efferent arteriole to hold filtration pressure up behind a stenosis; blockade releases that, intraglomerular pressure falls, and GFR settles modestly lower. A rise up to about 30% is accepted haemodynamics with preserved long-term outcomes — and its presence tells me the lesion is haemodynamically significant, which is diagnostic information, not harm. I monitor; I don't reflex-stop first-line renal and cardiovascular protection." [4]

"What single investigation best defines whether the lesion matters?" — "Clinically, the kidney sizes and the creatinine trajectory already tell me a great deal — preserved symmetric lengths mean viable parenchyma. For the artery itself, duplex with velocities and resistive indices in skilled hands gives functional data non-invasively; if I needed an anatomic answer I'd use his existing CTA, and if we ever went to the lab, a translesional pressure gradient — not the eyeball percentage — would decide significance of a borderline lesion." [4] [6]

"He lands in emergency twice in a month with acute pulmonary oedema, preserved ejection fraction, negative troponins. Same plan?" — "No — that changes everything. Recurrent flash pulmonary oedema is the Pickering syndrome: bilateral or functionally single-kidney stenosis producing volume-dependent hypertension that diuretics cannot permanently control. That is a defined revascularisation indication — the original Pickering series showed angioplasty or surgery abolished the episodes. I would repeat his imaging, because this presentation implies the disease is now bilateral or dominant, and refer him back for intervention." [5]

"What blood pressure target are you actually aiming for?" — "Individualised intensive control: SPRINT supports a systolic target around or below 120 in high-risk non-diabetic patients using standardised measurement, and KDIGO 2021 recommends standardised-office SBP under 120 in CKD where tolerated — I'd apply that cautiously given his age and the stenosis, watching renal function and symptoms, and I'd rather reach 120s slowly on three agents than chase a number into hypotension." [7]

Communication points

• Explain the no-stent decision as evidence, not inertia: "The trial that included patients exactly like you showed the stent didn't help beyond the tablets — and carried its own risks" [1].
• Name the adherence conversation without blame — most "resistance" is partial adherence, and saying so openly builds the partnership [3].
• Document the shared decision and the explicit triggers that would reopen the revascularisation question [5].